



# New Hampshire Medicaid Fee-for-Service Program Prior Authorization Drug Approval Form

Skysona™ (elivaldogene autotemcel)

DATE OF MEDICATION REQUEST:     /     /

## SECTION I: PATIENT INFORMATION AND MEDICATION REQUESTED

LAST NAME:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

FIRST NAME:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

MEDICAID ID NUMBER:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

DATE OF BIRTH:

				-					-				
--	--	--	--	---	--	--	--	--	---	--	--	--	--

GENDER:  Male  Female

Drug Name:

Strength:

Dosing Directions:

Length of Therapy:

## SECTION II: PRESCRIBER INFORMATION

LAST NAME:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

FIRST NAME:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

SPECIALTY:

NPI NUMBER:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

PHONE NUMBER:

				-					-				
--	--	--	--	---	--	--	--	--	---	--	--	--	--

FAX NUMBER:

				-					-				
--	--	--	--	---	--	--	--	--	---	--	--	--	--

## SECTION III: CLINICAL HISTORY

1. Is the patient a male at least four years of age but less than 18 years of age?  Yes  No
2. Is the diagnosis early, active cerebral adrenoleukodystrophy (CALD)?  Yes  No
3. Provide very-long-chain fatty acids (VLCFA) values and documentation:
  - C26:0, 1.30 + 0.45 (normal: 0.23 + 0.09): \_\_\_\_\_
  - C24:0/C22:0, 1.71 + 0.23 (normal: 0.84 + 0.10): \_\_\_\_\_
  - C26:0/C22:0, 0.07 + 0.03 (normal: 0.01 + 0.004): \_\_\_\_\_
4. Provide genetic testing results showing *ABCD1* mutation.

(Form continued on next page.)

Fax to DHHS; medication is administered in inpatient setting:

Phone: 1-866-675-7755     Fax: 1-888-603-7696

© 2021–2024 Prime Therapeutics Management LLC, a Prime Therapeutics LLC company

Review Date: 06/10/2024





# New Hampshire Medicaid Fee-for-Service Program Prior Authorization Drug Approval Form

Skysona™ (elivaldogene autotemcel)

DATE OF MEDICATION REQUEST:        /        /

**PATIENT LAST NAME:**

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

**PATIENT FIRST NAME:**

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

**SECTION III: CLINICAL HISTORY (Continued)**

5. Does the patient have active central nervous system (CNS) disease established by a central radiographic review of brain magnetic resonance imaging (MRI)?  Yes  No
  - Provide Loes score: \_\_\_\_\_ (34-point scale)
  - Does the MRI show demyelinating lesions with gadolinium enhancement?  Yes  No
6. What is the patient's neurological function score (NFS)? \_\_\_\_\_
7. Has the patient has been screened for the following conditions?  Yes  No
  - hepatitis B virus (HBV)
  - hepatitis C virus (HCV)
  - human T-lymphotrophic virus 1 and 2 (HTLV-1/HTLV-2)
  - human immunodeficiency virus 1 and 2 (HIV-1/HIV-2)
8. Does the patient have an active infection, including clinically important localized infections?  Yes  No
9. Will prophylaxis for infection be followed according to standard institutional guidelines?  Yes  No
10. Is the patient up to date with all age-appropriate vaccinations, in accordance with current vaccination guidelines?  Yes  No
11. Do you attest that the patient will receive periodic, life-long monitoring for hematological malignancies?  Yes  No
12. Will anti-retroviral medications be avoided one month prior to and throughout all cycles of apheresis?  Yes  No
13. Does the patient have head trauma induced disease?  Yes  No
14. Will Skysona be used to prevent the development of or treat adrenal insufficiency?  Yes  No
15. Has the patient had a hematopoietic stem cell transplant?  Yes  No
16. Does the patient have a known or available human leukocyte antigen (HLA)-matched willing family donor?  Yes  No

*(Form continued on next page.)*

**Fax to DHHS; medication is administered in inpatient setting:**

**Phone:** 1-866-675-7755      **Fax:** 1-888-603-7696

© 2021–2024 Prime Therapeutics Management LLC, a Prime Therapeutics LLC company

Review Date: 06/10/2024





# New Hampshire Medicaid Fee-for-Service Program Prior Authorization Drug Approval Form

Skysona™ (elivaldogene autotemcel)

DATE OF MEDICATION REQUEST:        /        /

**PATIENT LAST NAME:**

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

**PATIENT FIRST NAME:**

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

**SECTION III: CLINICAL HISTORY (Continued)**

Please provide any additional information that would help in the decision-making process. If additional space is needed, please use a separate sheet.

I certify that the information provided is accurate and complete to the best of my knowledge and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.

**PRESCRIBER'S SIGNATURE:** \_\_\_\_\_ **DATE:** \_\_\_\_\_

Facility where infusion to be provided: \_\_\_\_\_

Medicaid Provider Number of Facility: \_\_\_\_\_

**Fax to DHHS; medication is administered in inpatient setting:**

**Phone:** 1-866-675-7755      **Fax:** 1-888-603-7696

© 2021–2024 Prime Therapeutics Management LLC, a Prime Therapeutics LLC company

Review Date: 06/10/2024

